The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis.
The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis.
复制标题
DOI：
--
复制
发表时间：
2005
影响因子：
--
通讯作者：
B. Haraoui
中科院分区：
文献类型：
--
作者：
B. Haraoui
尽管传统的抗风湿药物(DMARD)作为单一或联合疗法的使用得到了优化，但25%至50%的类风湿关节炎(RA)患者仍有临床活动的滑膜炎伴进行性结构性关节损害。几项临床试验表明，抗肿瘤坏死因子(TNF)药物依那西普、英夫利昔单抗和阿达单抗单独或与甲氨蝶呤联合使用，对早期或确诊的RA患者的体征和症状以及功能都有持续的改善，放射学损害显著减缓。抗肿瘤坏死因子药物联合最佳剂量的MTX目前是治疗对传统DMARD反应不足的RA患者的最佳治疗方案。
Despite optimization of the use of the traditional disease modifying antirheumatic drugs (DMARD) as mono- or combination therapy, between 25% and 50% of patients with rheumatoid arthritis (RA) still have clinically active synovitis with progressive structural articular damage. Several clinical trials with the anti-tumor necrosis factor (TNF) agents etanercept, infliximab, and adalimumab, used alone or in combination with methotrexate, in patients with early or established RA have shown consistent improvement in signs and symptoms as well as function, with a dramatic slowing of radiographic damage. The anti-TNF agents combined with optimal doses of MTX currently constitute the best therapeutic regimen for the management of patients with RA failing to adequately respond to traditional DMARD.